IPO Year: 2022
Exchange: NASDAQ
SC 13G - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13G - Onconetix, Inc. (0001782107) (Subject)
SC 13G/A - Onconetix, Inc. (0001782107) (Subject)
NT 10-Q - Onconetix, Inc. (0001782107) (Filer)
424B4 - Onconetix, Inc. (0001782107) (Filer)
EFFECT - Onconetix, Inc. (0001782107) (Filer)
S-1/A - Onconetix, Inc. (0001782107) (Filer)
S-1/A - Onconetix, Inc. (0001782107) (Filer)
S-1 - Onconetix, Inc. (0001782107) (Filer)
S-1 - Onconetix, Inc. (0001782107) (Filer)
DEF 14C - Onconetix, Inc. (0001782107) (Filer)
8-K - Onconetix, Inc. (0001782107) (Filer)
PRE 14C - Onconetix, Inc. (0001782107) (Filer)
3/A - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
3 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
3 - Onconetix, Inc. (0001782107) (Issuer)
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (NASDAQ:ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix in the transaction had been corrected to Tungsten Advisors. The corrected release follows. Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or "the Company") (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced the signing and closing of a private placement of (i) 3,499 shares of the Company's Series C Convertible Preferred
CINCINATTI, Oh., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or "the Company") (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced the signing and closing of a private placement of (i) 3,499 shares of the Company's Series C Convertible Preferred Stock, $0.00001 par value (the "Series C Preferred Stock"), and (ii) warrants (the "Warrants") to acquire up to an aggregate of 591,856 additional shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for aggregate gross proceeds of approximately $2.0
CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved all proposals voted on at the Company's 2024 annual meeting of stockholders (the "Annual Meeting") held on September 5, 2024, and that its Board of Directors (the "Board of Directors" or "Board") approved a 1-for-40 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Tuesday, September 24, 2024. R
CINCINNATI, July 15, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. ("Onconetix" or the "Company") (NASDAQ:ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase 7,458,642 shares of its common stock having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The aggregate gross proceeds from the exercise of the existing warrants were approximately $1.11 million, before deducting placement agent fees and other offering expenses payable by the Company. H.C. Wainwright acted as the exclusive placement agent for this transaction. The Company expects to use the net proceeds from the t
CINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. ("Onconetix" or the "Company") (NASDAQ:ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares of its common stock originally issued in August 2022 and August 2023, having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The transaction is expected to close on or about July 12, 2024, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. The aggregate gross proceeds from the exerc
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
Shares of Tellurian Inc. (NASDAQ:TELL) rose sharply in today's pre-market trading after Woodside Energy announced plans to acquire the company for $900 million in all-cash deal. The implied enterprise value is around $1,200 million. Tellurian shares jumped 65% to $0.9422 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Netcapital Inc. (NASDAQ:NCPL) rose 43.8% to $0.1495 in pre-market trading after jumping more than 12% on Friday. Netcapital, last week, announced the launch of the beta version of its secondary trading platform. Serve Robotics Inc. (NASDAQ:SERV) gained 36.8% to $10.33 in pre-market trading. Serve Robotics shares jumped
Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from Benzinga Pro. Selective Insurance Group shares dipped 14.8% to $85.40 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Augmedix, Inc. (NASDAQ:AUGX) shares jumped 148.8% to $2.28 after the company announced it will be acquired by Commure. 60 Degrees Pha
Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results. Intuitive Surgical reported second-quarter revenue of $2.01 billion, beating the consensus estimate of $1.97 billion. The robotic-assisted surgery company reported quarterly adjusted earnings of $1.78 per share, beating analyst estimates of $1.54 per share. Intuitive Surgical shares jumped 6.7% to $444.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Serve Robotics Inc. (NASDAQ:SERV) gained 68.4% to $4.43 in pre-market trading after gaining over 12% on Thursday.
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 40 points on Thursday. Following the market opening Thursday, the Dow traded up 0.10% to 41,238.64 while the NASDAQ rose 0.22% to 18,036.66. The S&P 500 also rose, gaining, 0.21% to 5,600.18. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsIndustrials shares jumped by 0.6% on Thursday. In trading on Thursday, health care shares fell by 0.4%. Top Headline D.R. Horton, Inc. (NYSE:DHI) reported better-than-expected second-quarter earnings on Thursday. D.R. reported quarterly earnings of $4.10 per share which beat the analyst consensus
Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-market trading after the company and Darden Restaurants, Inc. (NYSE:DRI) jointly announced that Darden will acquire Chuy's Holdings. Chuy's Holdings and Darden entered into a definitive agreement in which Darden will acquire all of Chuy's outstanding stock for $37.50 per share in cash. The all-cash transaction has an enterprise value of approximately $605 million. Chuy’s Holdings shares jumped 47.4% to $37.27 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Onconetix, Inc. (NASDAQ:ONCO) gained 65% to $0.2458 in pre-market trading. On July 15, Onconetix announced cl
Onconetix, Inc. ("Onconetix" or the "Company") (NASDAQ:ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares of its common stock originally issued in August 2022 and August 2023, having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The transaction is expected to close on or about July 12, 2024, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction.The aggregate gross proceeds from the exercise of the existing warrants are expected to be approximately $1.1
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares rose 60.2% to $0.27 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.2 million. As per the press release, Q4 earnings came out 2 days ago. Mustang Bio (NASDAQ:MBIO) stock moved upwards by 31.21% to $0.98. The market value of their outstanding shares is at $27.7 million. Geovax Labs (NASDAQ:GOVX) shares increased by 24.32% to $1.38. The market value of their outstanding shares is at $3.4 million. Silk Road Medical (NASDAQ:SILK) stock increased by 23.67% to $26.8. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) shares rose 18.91% to $0.19. The market value of their outs
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 63.8% to $0.28 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. As per the news, the Q4 earnings report came out yesterday. Qualigen Therapeutics (NASDAQ:QLGN) stock rose 31.57% to $0.23. The company's market cap stands at $1.4 million. Mustang Bio (NASDAQ:MBIO) shares rose 30.66% to $0.98. The company's market cap stands at $27.6 million. Autonomix Medical (NASDAQ:AMIX) stock rose 25.92% to $1.7. The market value of their outstanding shares is at $32.0 million. Silk Road Medical (NASDAQ:SILK) shares moved upwards by 23.9% to $26.85. The market value of their outstanding shares is at $1.
-SEC Filing